The Robert J. Kleberg, Jr. and Helen C. Kleberg Center for Personalized Cancer Medicine
The generous support from the Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation has played a pivotal role in Vanderbilt-Ingram Cancer Center's ability to impact cancer discovery for nearly two decades.
Due to a long-term investment in basic and translational cancer science, support from the Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation has enabled Vanderbilt to emerge as an international leader in the early detection of cancer and precision cancer medicine—matching the right therapy to the right patient at the right time.
Programs in molecular imaging and genomics-based medicine have led to novel findings and more effective therapies for treating patients with head and neck cancers, leukemia, brain tumors, lung cancer, melanoma and a host of other cancer types.
Moreover, this partnership has served as a catalyst for additional funding from extramural sources that extend the scope and impact of our work.
The support from the Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation serves as a key ingredient in our mission to prevent, control and cure cancer and to have the greatest possible impact on the health and well-being of cancer patients and their families.
Related Links
News and Features
-
Study seeks to boost breast tumor immune response (02/08/18)
-
Pancreatic cancer development (08/31/17)
-
HDAC3 role in B-cell development (08/03/17)
-
PET imaging to predict tumor response (06/14/17)
-
Kleberg Foundation grant bolsters cancer drug discovery efforts (08/03/16)
-
New lead for ovarian cancer treatment (12/10/15)
-
Growth factor blockade targets breast tumors (08/14/14)
-
PET probe detects dying tumor cells (05/08/14)
